Jincheng Pharm(300233)

Search documents
5月14日晚间重要公告一览
Xi Niu Cai Jing· 2025-05-14 10:14
万科A:第一大股东深铁集团拟提供不超过15.52亿元借款 5月14日晚,万科A(000002)发布公告称,公司第一大股东深圳市地铁集团有限公司拟向公司提供借 款,借款金额不超过15.52亿元,用于偿还公司在公开市场发行的债券的本金与利息,借款利率为每笔 借款提款日前一工作日全国银行间同业拆借中心公布的1年期贷款市场报价利率(LPR)减76个基点。 资料显示,万科A成立于1984年5月,主营业务是房地产、物业的开发与服务。 所属行业:房地产–房地产开发–住宅开发 易德龙:一季度净利润4176.98万元 同比增长34.19% 所属行业:房地产–房地产开发–商业地产 大金重工:子公司与欧洲能源企业签10亿元海上风电项目合同 5月14日晚,大金重工(002487)发布公告称,全资子公司蓬莱大金海洋重工有限公司于近日与欧洲某 能源企业签署了价值约10亿元的《单桩基础制造、供应和运输合同》。根据合同,蓬莱大金将为欧洲某 海上风电项目提供超大型单桩产品,并承担海运服务,预计2027年交付完毕。 资料显示,大金重工成立于2003年9月,主营业务是风力发电设备制造。 所属行业:电力设备–风电设备–风电零部件 5月14日晚,易德 ...
通化东宝精蛋白人胰岛素在尼加拉瓜获批;浩欧博回复年报信息披露监管工作函
Mei Ri Jing Ji Xin Wen· 2025-05-13 23:34
Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]
金城医药:与Theramex签署权益许可和经销协议
news flash· 2025-05-13 10:44
金城医药:与Theramex签署权益许可和经销协议 智通财经5月13日电,金城医药(300233.SZ)公告称,金城医药近日与Theramex HQ UK Limited签署了 《权益许可和经销协议》,获得用于绝经后妇女雌激素缺乏症状的连续联合激素替代疗法(HRT)的雌 二醇黄体酮软胶囊(Bijuva)在中国境内(包括中国大陆、香港和澳门)的独家排他的商业化权益。此 次合作不涉及关联交易,亦不构成重大资产重组。协议签署预计不会对公司本年度财务状况和经营业绩 构成重大影响。 ...
金城医药(300233) - 关于签署权益许可和经销协议的公告
2025-05-13 10:40
证券代码:300233 证券简称:金城医药 公告编号:2025-042 山东金城医药集团股份有限公司 关于签署权益许可和经销协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记 载、误导性陈述或重大遗漏。 特别提示: 1、本协议的签署不会对公司本年度财务状况及经营业绩构成重大影响。 2、本次合作不构成关联交易,亦不构成重大资产重组。 一、协议签署情况 山东金城医药集团股份有限公司(以下简称"公司"或"金城医药")近日与 Theramex HQ UK Limited (以下简称"Theramex")签署了《权益许可和经销协议》 (以下简称"本协议"或"协议")。双方就用于绝经后妇女雌激素缺乏症状的连 续联合激素替代疗法(HRT)的雌二醇黄体酮软胶囊(以下简称"Bijuva",为其 商品名)在中国境内的权益许可和经销协议达成合作,金城医药获得该产品在中国 大陆、香港和澳门的独家排他的商业化权益。 本次签署合作协议不涉及关联交易,亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。本协议无需提交公司董事会、股东大会审议批准。 二、协议对方介绍 5、履约能力分析:Theramex ...
金城医药(300233) - 关于参加2025年山东辖区上市公司投资者网上集体接待日活动的公告
2025-05-12 10:12
本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司 关于参加 2025 年山东辖区上市公司投资者网上集体 接待日活动的公告 为进一步加强与投资者的互动交流,山东金城医药集团股份有限公司(以下 简称"公司")将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动",现 将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (http://rs.p5w.net);或关注微信公众号(名称:全景财经);或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月15日(周四)15:00-16:30。 届时公司董事会秘书朱晓刚先生、财务总监刘静女士将在线就公司 2024 年度业 绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题,与投资 者进行沟通与交流,欢迎广大投资者踊跃参与! 证券代码:300233 证券简称:金城医药 公告编号:2025-041 特此公告。 2025 年 5 月 12 日 - 1 - 山东金城医药集团股 ...
淄股一周:30股飘红,未名医药涨幅23.29%
Qi Lu Wan Bao Wang· 2025-05-09 13:19
Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]
转基因概念下跌1.12%,6股主力资金净流出超千万元
Zheng Quan Shi Bao Wang· 2025-05-08 08:44
Group 1 - The genetically modified (GM) concept sector declined by 1.12%, ranking among the top declines in concept sectors, with leading decliners including Fengle Seed Industry, Qianyuan High-Tech, and Wanxiang DeNong [1][2] - Among the GM concept stocks, only four experienced price increases, with Ba Tian Co., Qian Qian Bio, and Top Cloud Agriculture rising by 2.16%, 1.92%, and 1.85% respectively [1][2] - The GM concept sector saw a net outflow of 123 million yuan from main funds today, with 11 stocks experiencing net outflows, and six stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The stock with the highest net outflow was Qianyuan High-Tech, with a net outflow of 28.98 million yuan, followed by Fengle Seed Industry, Dabeinong, and Shennong Seed Industry with net outflows of 25.65 million yuan, 22.57 million yuan, and 18.05 million yuan respectively [2][3] - The stocks with the highest net inflows included Top Cloud Agriculture, Longping High-Tech, and Ba Tian Co., with net inflows of 7.65 million yuan, 7.01 million yuan, and 2.32 million yuan respectively [3]
金城医药(300233) - 2024年年度权益分派实施公告
2025-05-06 09:56
证券代码:300233 证券简称:金城医药 公告编号:2025-040 山东金城医药集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、公司 2024 年年度权益分派方案已获 2025 年 4 月 22 日召开的 2024 年年度股 东大会审议通过,具体内容为:以扣除公司回购专户中已回购股份后的总股本 379,331,587 股为基数(公司总股本 383,874,587 股,扣除公司回购专户股份数量 4,543,000 股),向股权登记日登记在册的全体股东每 10 股派发现金红利人民币 1.5 元(含税),共计派发现金红利人民币 56,899,738.05 元(含税)。本次利润分配不 送红股,不以资本公积金转增股本。 2、因公司回购专户的股份不享有参与利润分配的权利,公司本次实际派发现金 分红总额=(383,874,587 股-4,543,000 股)÷10×1.5 元/股=56,899,738.05 元。 本次权益分派实施后计算除权除息价格时,按总股本(含回购股份,下同)计算的每 10 股派息( ...
金城医药(300233) - 2025 Q1 - 季度财报
2025-04-28 09:55
Financial Performance - The company's revenue for Q1 2025 was ¥721,919,205.16, a decrease of 22.52% compared to ¥931,696,552.76 in the same period last year[5]. - Net profit attributable to shareholders was ¥35,054,760.33, down 57.75% from ¥82,971,349.76 year-on-year[5]. - Basic earnings per share decreased by 59.09% to ¥0.09 from ¥0.22 in the same period last year[5]. - Net profit for the current period is ¥36,298,903.66, a decline of 59.3% compared to ¥89,158,928.05 in the previous period[23]. - Basic and diluted earnings per share are both ¥0.09, down from ¥0.22 in the previous period[24]. Cash Flow - The net cash flow from operating activities was -¥8,565,391.95, a decline of 120.70% compared to ¥41,373,196.64 in the previous year[5]. - Cash flow from operating activities shows a net outflow of ¥8,565,391.95, compared to a net inflow of ¥41,373,196.64 in the previous period[25]. - The net cash flow from financing activities was -¥65,461,298.33, a decline of 354.21% compared to a net inflow of ¥25,751,266.86 in the previous year[14]. - Cash and cash equivalents decreased to ¥853,676,725.38 from ¥917,670,953.09[17]. - Cash and cash equivalents at the end of the period amount to ¥796,398,844.56, down from ¥921,001,178.30 at the end of the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,471,384,233.67, down 2.38% from ¥5,604,990,741.71 at the end of the previous year[5]. - Total current assets amount to ¥2,184,257,009.16, a decrease from ¥2,258,285,131.73 at the beginning of the period[18]. - Total liabilities decreased to ¥1,657,956,535.57 from ¥1,772,836,587.70[19]. - Total assets and equity decreased to ¥5,471,384,233.67 and ¥3,813,427,698.10 respectively, from ¥5,604,990,741.71 and ¥3,832,154,154.01 in the previous period[20]. - The company has a total equity of ¥3,813,427,698.10, unchanged from the previous period[19]. Operational Metrics - The decline in revenue was primarily due to a decrease in the prices of pharmaceutical intermediates and the impact of national centralized procurement on sales volume and prices of certain products[9]. - Sales expenses decreased by 56.48% to ¥74,794,902.94, attributed to reduced market promotion activities due to centralized procurement[13]. - Total operating costs for the current period are ¥682,091,200.85, down 17.3% from ¥824,597,996.18 in the previous period[21]. - The company reported a significant increase in accounts receivable by 144.70% to ¥51,960,111.27 due to increased issuance of pledged notes[12]. - The company experienced a significant increase in credit impairment losses, totaling ¥7,015,544.06, compared to ¥2,270,345.38 in the previous period[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,604[16]. - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.46% of shares, totaling 78,552,154 shares, with 17,588,900 shares pledged[16]. Inventory and Expenditures - The company’s inventory stands at ¥596,359,058.41, slightly down from ¥598,863,558.41[17]. - The company has ongoing development expenditures of ¥252,798,405.62, up from ¥240,729,227.18[18]. Future Outlook - The company plans to implement new accounting standards starting from 2025, which may impact future financial reporting[27].
金城医药:2025年第一季度净利润3505.48万元,同比下降57.75%
news flash· 2025-04-28 09:54
Group 1 - The core point of the article indicates that Jincheng Pharmaceutical (300233) reported a revenue of 722 million yuan in the first quarter of 2025, representing a year-on-year decline of 22.52% [1] - The net profit for the same period was 35.05 million yuan, which reflects a significant year-on-year decrease of 57.75% [1]